Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of trihydroxyflavone in preparing medicament used for preventing and treating abdominal aortic aneurysm

A technology of trihydroxyflavonoids and abdominal aortic aneurysm, applied in the direction of drug combination, antineoplastic drugs, antipyretics, etc., can solve problems such as uncertain conclusions, no literature reports, and influence on the formation of abdominal aortic aneurysm

Active Publication Date: 2015-11-25
THE INST OF BASIC MEDICAL SCI OF CHINESE ACAD OF MEDICAL SCI
View PDF4 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] 2) Antihypertensive drugs, although there are many randomized clinical trials exploring whether antihypertensive drugs can delay tumor growth, but the current conclusions are uncertain
[0014] BAI can significantly inhibit myocardial cell injury after ischemia-reperfusion, the specific molecular mechanism remains to be studied, and whether it can affect the formation of abdominal aortic aneurysm has not been reported in the literature

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of trihydroxyflavone in preparing medicament used for preventing and treating abdominal aortic aneurysm
  • Application of trihydroxyflavone in preparing medicament used for preventing and treating abdominal aortic aneurysm
  • Application of trihydroxyflavone in preparing medicament used for preventing and treating abdominal aortic aneurysm

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0056] Embodiment 1. Establishment of the model

[0057] 1. Identification of Apoe- / - mice

[0058] Following the methods well known to those skilled in the art, the mice were identified by PCR and the Apoe- / - mice were passaged. Three primers oIMR180, oIMR181 and oIMR182 recommended by Jackson Laboratory (Bar Harbor, ME) were used (primer sequences are available from the supplier).

[0059] 2. Identification of AngII-induced Apoe- / - mice to produce an abdominal aortic aneurysm model

[0060] Angiotensin II (angiotensin II, Ang II) is an important member of the renin-angiotensin system, and activates downstream signaling pathways such as MAPKs (p38, ERK, JNK) by binding to its receptor AT1R, thereby inducing the generation of oxygen free radicals, cell Apoptosis, inflammatory cytokine expression, and matrix metalloproteinase synthesis. Angiotensin II stimulates Apoe- / - mice, which can simulate almost all the pathogenesis of abdominal aortic aneurysm formation, with an incid...

Embodiment 2

[0063] Example 2. Therapeutic regimen

[0064] 1. BAI intraperitoneal injection: BAI (Sigma, 465119) powder was dissolved in sterile saline (saline, vehicle) to form a suspension with a concentration of 7.5 mg / mL. BAI concentration can be between 20-200mg / kg / d. In this embodiment, two concentrations and doses are selected: 30 mg / kg / d and 100 mg / kg / d.

[0065] 2. Experimental animals are divided into 6 groups:

[0066] The AngII experimental group included:

[0067] Control group (VehicleApoe- / -, VehApoe- / -),

[0068] BAI low dose group (BAI-30Apoe- / -),

[0069] BAI high dose group (BAI-100Apoe- / -);

[0070] Saline control groups included:

[0071] Control group (VehicleApoe- / -, VehApoe- / -),

[0072] BAI low dose group (BAI-30Apoe- / -),

[0073] BAI high dose group (BAI-100Apoe- / -).

[0074] BAI pre-stimulation was started one week before AngII stimulation, the dose was 30mg / kg / d, 100mg / kg / d, once a day at the same time. Grab the mouse, disinfect the left groin area wi...

Embodiment 3

[0080] Example 3.Western detection

[0081] 1. Total Protein Extraction from Mouse Aorta

[0082] The extraction of mouse aortic tissue protein was done by completely stripping off the perivascular tissue and adventitia after perfusion, weighing first, and then adding RIPA lysate to 3 times the volume of the tissue block, fully homogenized with a glass homogenizer, and iced. Bath 30min. Ultrasonic instrument 7W power ultrasonic 10sec, interval 1min, a total of 3 times, and then ice bath for 30min. Centrifuge at 12500rpm for 30min at 4°C. Take the supernatant and measure the protein concentration by BCA method, add it to a new EP tube, add 5× loading buffer, mark it after mixing, boil in boiling water for 10 minutes, store at -20°C for short-term use, and store in long-term Standby at -80°C.

[0083] 2. Protein Concentration Determination

[0084] Protein concentration BCA determination method: BCA (BicinchoninicAcid) is a pair of monovalent copper ions (Cu + ) sensitive,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of trihydroxyflavone in preparing medicament used for preventing and treating abdominal aortic aneurysm. It is found that trihydroxyflavone can significantly inhibit formation of the abdominal aortic aneurysm induced by angiotensin II. The inhibiting effect mainly comprises inhibiting oxyradical generation, reducing inflammatory cell infiltration, inhibiting inflammatory factor secretion, and reducing expression level and enzymatic activity of matrix metalloproteinase 2 and matrix metalloproteinase 9, meanwhile, trihydroxyflavone can inhibit AngII signaling pathway by down-regulating AT1R.

Description

technical field [0001] The invention relates to the use of trihydroxyflavone in medicine for treating or preventing abdominal aortic aneurysm. Background technique [0002] An aneurysm is defined as a morphological change in which the arterial walls lose parallelism, eventually leading to dilation and rupture of the aneurysm. Abdominal aortic aneurysm is one of the most common types, and most commonly occurs in the lower segment of the abdominal aorta and renal arteries. Several studies have shown that its diagnostic criteria are that the maximum anteroposterior diameter exceeds 3 cm or is greater than 1.5 times the normal. [0003] The occurrence and development of abdominal aortic aneurysm is a dynamic process, and its main mechanisms include oxidative stress, inflammatory response, degradation of extracellular matrix, and apoptosis of medial smooth muscle cells. It is crucial to explore the factors that promote the progression of arterial walls from loss of parallelism t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61P35/00A61P9/00A61P29/00
Inventor 刘德培陈厚早王放
Owner THE INST OF BASIC MEDICAL SCI OF CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com